Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Denkinger et al., Nature Cancer, doi:10.1038/s43018-022-00503-w
https://c19early.org/denkinger.html